BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Wang X, Xiao Z, Gong J, Liu Z, Zhang M, Zhang Z. A prognostic nomogram for lung adenocarcinoma based on immune-infiltrating Treg-related genes: from bench to bedside. Transl Lung Cancer Res 2021;10:167-82. [PMID: 33569302 DOI: 10.21037/tlcr-20-822] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
Number Citing Articles
1 Zhang C, Song X, Wang C. COL22A1 and DNAH8 mutations are associated with tumor mutation burden and prognosis of lung adenocarcinoma patients.. [DOI: 10.21203/rs.3.rs-2162636/v1] [Reference Citation Analysis]
2 Xiaochun H, Feixiong P, Shengsong O, Xiaojiao W, Yuju X, Yanhua L, Schmalz G. Identification and Validation of an Inflammatory Response-Related Polygenic Risk Score as a Prognostic Marker in Hepatocellular Carcinoma. Disease Markers 2022;2022:1-14. [DOI: 10.1155/2022/1739995] [Reference Citation Analysis]
3 Lee JY, Kannan B, Lim BY, Li Z, Lim AH, Loh JW, Ko TK, Ng CC, Chan JY. The Multi-Dimensional Biomarker Landscape in Cancer Immunotherapy. Int J Mol Sci 2022;23:7839. [PMID: 35887186 DOI: 10.3390/ijms23147839] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
4 Liu L, Liu J, Deng X, Tu L, Zhao Z, Xie C, Yang L. A nomogram based on A-to-I RNA editing predicting overall survival of patients with lung squamous carcinoma. BMC Cancer 2022;22:715. [PMID: 35768804 DOI: 10.1186/s12885-022-09773-0] [Reference Citation Analysis]
5 Gao Z, Zhang Q, Zhang X, Song Y. Advance of T regulatory cells in tumor microenvironment remodeling and immunotherapy in pancreatic cancer. Eur J Inflamm 2022;20:1721727X2210929. [DOI: 10.1177/1721727x221092900] [Reference Citation Analysis]
6 Xue Q, Wang Y, Zheng Q, Chen L, Jin Y, Shen X, Li Y. Construction of a prognostic immune-related lncRNA model and identification of the immune microenvironment in middle- or advanced-stage lung squamous carcinoma patients. Heliyon 2022;8:e09521. [DOI: 10.1016/j.heliyon.2022.e09521] [Reference Citation Analysis]
7 Wang Z, Hu F, Chang R, Yu X, Xu C, Liu Y, Wang R, Chen H, Liu S, Xia D, Chen Y, Ge X, Zhou T, Zhang S, Pang H, Fang X, Zhang Y, Li J, Hu K, Cai Y. Development and Validation of a Prognostic Model to Predict Overall Survival for Lung Adenocarcinoma: A Population-Based Study From the SEER Database and the Chinese Multicenter Lung Cancer Database. Technol Cancer Res Treat 2022;21:153303382211332. [DOI: 10.1177/15330338221133222] [Reference Citation Analysis]
8 Chen H, Shen W, Ni S, Sang M, Wu S, Mu Y, Liu K, Li N, Zhu L, Xu G. Construction of an immune-related lncRNA signature as a novel prognosis biomarker for LUAD. Aging (Albany NY) 2021;13:20684-97. [PMID: 34438369 DOI: 10.18632/aging.203455] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 4.0] [Reference Citation Analysis]
9 Xu Q, Chen Y. An Aging-Related Gene Signature-Based Model for Risk Stratification and Prognosis Prediction in Lung Adenocarcinoma. Front Cell Dev Biol 2021;9:685379. [PMID: 34277626 DOI: 10.3389/fcell.2021.685379] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 4.5] [Reference Citation Analysis]
10 Principe DR, Chiec L, Mohindra NA, Munshi HG. Regulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer. Front Oncol 2021;11:684098. [PMID: 34141625 DOI: 10.3389/fonc.2021.684098] [Cited by in Crossref: 14] [Cited by in F6Publishing: 16] [Article Influence: 7.0] [Reference Citation Analysis]